Chilblains observed during the COVID-19 pandemic cannot be distinguished from classic, cold-related chilblains

Type 1 interferon (IFN-I) response induced by SARS-CoV-2 has been hypothesized to explain the association between chilblain lesions (CL) and SARS-CoV-2 infection. To explore direct cytopathogenicity of SARS-CoV-2 in CL and to focus on IFN-I expression in patients with chilblains. A monocentric cohort of 43 patients presenting with CL from April 2020 to May 2021 were included. During this period, all CL were, a priori, considered to be SARS-CoV-2-related. RT-qPCR on nasopharyngeal swabs and measurements of anti-SARS-CoV-2 antibodies were performed. Anti-SARS-CoV-2 immunostainings as well as SARS-CoV-2 RT-qPCR were performed on biopsy specimens of CL and controls. Expression of MX1 and IRF7 was analysed on patients’ biopsy specimens and/or PBMC and compared with controls and/or chilblains observed before the pandemic. Serum IFN-α was also measured. RT-qPCR was negative in all patients and serological tests were positive in 11 patients. Immunostaining targeting viral proteins confirmed the lack of specificity. SARS-CoV-2 RNA remained undetected in all CL specimens. MX1 immunostaining was positive in CL and in pre-pandemic chilblains compared to controls. MX1 and IRF7 expression was significantly increased in CL specimens but not in PBMC. Serum IFN-α was undetected in CL patients. CL observed during the pandemic do not appear to be directly related to SARS-CoV-2 infection, either based on viral cytopathogenicity or high IFN-I response induced by the virus.

[1]  J. Ramos-Rincón,et al.  Are the chilblain‐like lesions observed during the COVID‐19 pandemic due to severe acute respiratory syndrome coronavirus 2? Systematic review and meta‐analysis , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  S. Baggio,et al.  Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity , 2021, Cell Reports.

[3]  L. Herrinton,et al.  Epidemiologic Analysis of Chilblains Cohorts Before and During the COVID-19 Pandemic. , 2021, JAMA dermatology.

[4]  P. Boor,et al.  Nachweismethoden von SARS-CoV-2 in Gewebe , 2021, Der Pathologe.

[5]  C. Knabbe,et al.  Evidence of Long-Lasting Humoral and Cellular Immunity against SARS-CoV-2 Even in Elderly COVID-19 Convalescents Showing a Mild to Moderate Disease Progression , 2021, medRxiv.

[6]  F. Fantini,et al.  Relapse of chilblain‐like lesions during the second wave of coronavirus disease 19 , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  J. Cappel,et al.  Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms , 2021, Mayo Clinic Proceedings.

[8]  E. Freeman,et al.  Emerging Evidence of the Direct Association Between COVID-19 and Chilblains. , 2020, JAMA dermatology.

[9]  R. Aschoff,et al.  Type I Interferon Signature in Chilblain-Like Lesions Associated with the COVID-19 Pandemic , 2020, Dermatopathology.

[10]  D. Bessis.  Impaired type I interferon response in SARS‐CoV‐2 infection: looking through the cutaneous window , 2020, The British journal of dermatology.

[11]  G. Leftheriotis,et al.  Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic. , 2020, JAMA dermatology.

[12]  Alka A. Potdar,et al.  Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease , 2020, Gastroenterology.

[13]  N. Kluger.  Why are chilblains underreported in Nordic countries during the COVID‐19 pandemic? An analysis of Google Trends , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[15]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[16]  S. Vermeire,et al.  Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon , 2020, Journal of Crohn's & colitis.

[17]  R. Balestri,et al.  Do we have serological evidences that chilblain‐like lesions are related to SARS‐CoV‐2? A review of the literature , 2020, Dermatologic therapy.

[18]  A. Herman,et al.  Chilblains and COVID‐19: why SARS‐CoV‐2 endothelial infection is questioned , 2020, The British journal of dermatology.

[19]  G. Nuovo,et al.  The differing pathophysiologies that underlie COVID‐19‐associated perniosis and thrombotic retiform purpura: a case series , 2020, The British journal of dermatology.

[20]  R. Papa,et al.  Monogenetic causes of chilblains, panniculitis and vasculopathy: the Type I interferonopathies , 2020 .

[21]  C. Charpentier,et al.  New insights in COVID-19–associated chilblains: A comparative study with chilblain lupus erythematosus , 2020, Journal of the American Academy of Dermatology.

[22]  L. Requena,et al.  COVID‐19 chilblain‐like lesion: immunohistochemical demonstration of SARS‐CoV‐2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction‐negative patient , 2020, The British journal of dermatology.

[23]  R. Botella-Estrada,et al.  Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic , 2020, JAMA dermatology.

[24]  C. Hermans,et al.  Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic. , 2020, JAMA dermatology.

[25]  J. Rodríguez-Peralto,et al.  SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases , 2020, The British journal of dermatology.

[26]  B. King,et al.  When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection , 2020, Journal of the American Academy of Dermatology.

[27]  T. Lazzarotto,et al.  Major cluster of paediatric ‘true’ primary chilblains during the COVID‐19 pandemic: a consequence of lifestyle changes due to lockdown , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[28]  D. Lipsker.  A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2? , 2020, Medical Hypotheses.

[29]  J. Lipoff,et al.  Timing of PCR and antibody testing in patients with COVID-19–associated dermatologic manifestations , 2020, Journal of the American Academy of Dermatology.

[30]  F. Benhadou,et al.  Chilblains. , 2019, VASA. Zeitschrift fur Gefasskrankheiten.

[31]  Y. Crow,et al.  Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.

[32]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.